ArticleDiscoveries (Craiova, Romania)2019
Immunotherapy for Breast Cancer: First FDA Approved Regimen.
Article in Discoveries (Craiova, Romania), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review.Cardio-oncology (London, England) · 2026Review
- Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.Current topics in medicinal chemistry · 2026Review
- [Cancers · 2023Article
- LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells.Biomedicines · 2022Article
- Evaluation PD-L1, CD8 and CD20 as early predictor and tracking markers for breast cancer (BC) in Egypt.Heliyon · 2022Article
- Thyroid-related adverse events induced by immune checkpoint inhibitors.Frontiers in endocrinology · 2022Review
- VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes.Cancers · 2021Article
- Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.Breast cancer research and treatment · 2021Article
- Article
- Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer.PloS one · 2021Article
- Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.Frontiers in pharmacology · 2021Review
- Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study.Breast cancer (Dove Medical Press) · 2021Article
- Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy.Frontiers in oncology · 2021Review
- Drug Repurposing for Triple-Negative Breast Cancer.Journal of personalized medicine · 2020Review
- Article
- Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis.Journal of Cancer · 2020Article
- Immunomodulatory Drugs in Melanoma Brain Metastases.Discoveries (Craiova, Romania) · 2019Review
- Immunotherapy as a Turning Point in the Treatment of Melanoma Brain Metastases.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1 in 8 women will be affected by breast cancer, which is the most diagnosed malignancy among women. Although breast cancer was regarded as "immunologically cold", recent studies demonstrate that immunotherapy can be successful employed in combination regimens for the treatment of triple negative breast cancer, an aggressive type of breast cancer without many treatment options available. In March 2019, the US Food and Drug Administration granted accelerated approval for the first immunotherapy-based regimen comprising atezolizumab in combination with protein-bound paclitaxel for patients with advanced metastatic TNBC, expressing programmed cell death-ligand 1 (PD-L1) and without previous systemic treatment for metastatic disease. This immunotherapy-based regimen is not only a promising therapy for the TNBC patients, but it also represents an inspiring proof of concept for the development of more efficient advanced immunotherapy-based strategies for breast cancer treatment in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.